A Dose Finding Study of [177Lu]Lu-DOTA-TATE in Newly Diagnosed Glioblastoma in Combination With Standard of Care and in Recurrent Glioblastoma as a Single Agent.
Clinical trial NCT05109728 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT05109728
- Sponsor
- Novartis Pharmaceuticals
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2022-05-10
- Primary completion
- 2025-12-03
- Enrollment
- 65
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.